Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation:a nationwide study by Schjerning Olsen, Anne-Marie et al.
 
  
 
Aalborg Universitet
Risk of gastrointestinal bleeding associated with oral anticoagulation and non-
steroidal anti-inflammatory drugs in patients with atrial fibrillation
a nationwide study
Schjerning Olsen, Anne-Marie; McGettigan, Patricia; Gerds, Thomas Alexander; Fosbøl, Emil
Loldrup; Olesen, Jonas Bjerring; Sindet-Pedersen, Caroline; Staerk, Laila; Hansen, Morten
Lock; Pallisgaard, Jannik Langtved; Køber, Lars; Torp-Pedersen, Christian; Gislason, Gunnar
Hilmar; Lamberts, Morten
Published in:
European heart journal. Cardiovascular pharmacotherapy
DOI (link to publication from Publisher):
10.1093/ehjcvp/pvz069
Publication date:
2019
Document Version
Accepted author manuscript, peer reviewed version
Link to publication from Aalborg University
Citation for published version (APA):
Schjerning Olsen, A-M., McGettigan, P., Gerds, T. A., Fosbøl, E. L., Olesen, J. B., Sindet-Pedersen, C., Staerk,
L., Hansen, M. L., Pallisgaard, J. L., Køber, L., Torp-Pedersen, C., Gislason, G. H., & Lamberts, M. (2019). Risk
of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in
patients with atrial fibrillation: a nationwide study. European heart journal. Cardiovascular pharmacotherapy.
https://doi.org/10.1093/ehjcvp/pvz069
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
1  
 
Risk of gastrointestinal bleeding associated with oral anticoagulation 
and non-steroidal anti-inflammatory drugs in patients with atrial 
fibrillation: a nationwide study  
Anne-Marie Schjerning Olsen, MD (1), Patricia McGettigan, MD (2), Thomas Alexander Gerds, 
PhD ( 3), Emil Loldrup Fosbøl, MD (3,4), Jonas Bjerring Olesen, MD (1), Caroline Sindet-
Pedersen, MD (1), Laila Staerk, MD (1), Morten Lock Hansen, MD (1), Jannik Langtved 
Pallisgaard, MD (1), Lars Køber, MD (4), Christian Torp-Pedersen, MD (5), Gunnar Hilmar 
Gislason, MD (1,3,6,7), Morten Lamberts, MD (1) 
 
Affiliation 
(1) Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Denmark 
(2) William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, 
Queen Mary University of London, United Kingdom 
(3) The Danish Heart Foundation, Copenhagen, Denmark 
(4) Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Denmark 
(5) Institute of Health, Science and Technology, Aalborg University, Denmark 
(6) Faculty of Health and Medical Sciences, University of Copenhagen, Denmark 
(7) The National Institute of Public Health, University of Southern Denmark, Denmark 
 
Short title: Schjerning, NOACs and NSAIDs in AF patients 
 
Address for correspondence and the institution, where the work was performed: 
Anne-Marie Schjerning Olsen, MD, PhD, Post.doc 
Manuscript Highlighted
© Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2019. 
For permissions, please email: journals.permissions@oup.com 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz069/5631912 by Aalborg U
niversity Library user on 20 N
ovem
ber 2019
2  
 
Department of Cardiology, Herlev and Gentofte University Hospital 
Post 635, Kildegaardsvej 28, 2900 Hellerup, Denmark. 
Tel: +45 60169340 
Fax number: +45 70201282 
E-mail: amschjerning@gmail.com 
Word count:  4777 (max 5000) 
Abstract:  248 (max 250)  
Tables/Figures: 1/4    
References: 38 
 
 
 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz069/5631912 by Aalborg U
niversity Library user on 20 N
ovem
ber 2019
3  
 
Abstract  
Aims: Non-vitamin K antagonist oral anticoagulants (NOACs) are displacing Vitamin K 
antagonists (VKAs) for stroke prophylaxis in patients with atrial fibrillation (AF). Concomitant use 
of non-steroidal anti-inflammatory drugs (NSAIDs) could increase gastrointestinal bleeding (GIB) 
risks among these patients. The aim of this study was to examine the risk of GIB among Danish AF 
patients taking oral anticoagulants (OACs) and NSAID.  
Methods and results: Using nationwide administrative registries, we determined concomitant 
NSAID use among anticoagulant-naïve patients with AF initiating OACs between August 2011 and 
June 2017. We calculated short-term absolute risks differences and hazard ratios (HRs) for GIB 
based on multiple adjusted cause-specific Cox regressions with time-dependent NSAID treatment.  
Among 41,183 patients (median age 70 years (IQR 64-78); 55% men), 21% of patients on NOACs 
and 18% on VKA were co-prescribed NSAIDs. The differences in absolute risk (95% Confidence 
Interval (CI)) of GIB within 14 days of commencing concomitant NSAID therapy (versus no 
concomitant NSAID therapy) were 0.10% (0.04%-0.18%) for NOACs and 0.13% (0.03%-0.24%) 
for VKA. NOACs overall were associated with less GIB than VKA (HR 0.77 [95% CI 0.69-0.85]). 
Compared with OACs alone, concomitant NSAIDs doubled the GIB risk associated with NOACs 
overall (HR 2.01 [95% CI 1.40-2.61] and with VKA (HR 1.95 [95% CI 1.21-2.69]). 
Conclusion: Among this nationwide AF population taking OACs, concomitant NSAID therapy 
increased the short-term absolute risk of GIB. NOACs alone were associated with lower GIB risks 
than VKA but concomitant NSAIDs abolished this advantage. The findings align with post-hoc 
analyses from randomized studies. Physicians should exercise appropriate caution when prescribing 
NSAIDs for patients with AF taking NOACs or VKA. 
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Introduction 
For decades, vitamin K antagonists (VKAs), commonly warfarin, have been the preferred treatment 
for stroke prophylaxis in patients with atrial fibrillation (AF).1 More recently, the non-vitamin-K-
antagonist oral anticoagulants (NOACs) are available as alternatives. In Denmark, dabigatran, a 
direct thrombin inhibitor, was marketed for AF in August 2011 followed by the Factor Xa 
inhibitors, rivaroxaban, apixaban and edoxaban, in February 2012, January 2013 and June 2016 
respectively. Unlike VKAs, NOACs do not need frequent monitoring with blood tests. Their uptake 
has been rapid.2, 3 While they have similar or safer overall bleeding risk profiles compared with 
VKAs, some have been associated with significantly more gastrointestinal bleeding than warfarin.4-
9 
Non-steroidal anti-inflammatory drugs (NSAIDs) are effective, widely-used analgesics. Much 
attention has been given to their gastrointestinal safety and consequently, the incidence of NSAID-
associated upper gastrointestinal bleeding has fallen.10-12 Despite this, the case-fatality rate has not 
declined.13 When co-prescribed with warfarin for cardiovascular patients, NSAIDs have been 
associated with a substantial independent risk of bleeding, even with short term use (<14 days).14, 15 
Although NSAIDs are discouraged in people with cardiovascular disease, pain is common and in 
the absence of more effective, safer anti-inflammatory analgesics, they are frequently prescribed.14, 
16, 17 Although NSAID is a well-recognized risk factor for bleeding in patients with AF, and 
included in the HASBLED score, the risk of gastrointestinal bleeding associated with concomitant 
NOAC and NSAID prescribing has not been investigated. As both drug groups are in widespread 
use, any risk is of considerable public health concern. We therefore examined the risk of 
gastrointestinal bleeding associated with NSAID therapy added to a VKA or NOAC among patients 
with AF in a nationwide cohort. 
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Methods 
Data sources 
In Denmark, each resident is registered with a unique, permanent identification number that enables 
individual-level linkage between several nationwide administrative registries. Four were linked at 
individual patient level in this study. The Danish National Patient Registry holds data on all hospital 
admission since 1978. Each admission is registered with one main discharge diagnosis and, if 
appropriate, one or more supplementary diagnoses using the International Classification of Diseases 
(ICD-8 until 1994; ICD-10 from 1994).18 The civil registration registry records vital status data. The 
National Prescription Registry holds information on the date of dispensing, quantity, strength, and 
formulation of all prescriptions dispensed from Danish pharmacies since 1995 and is based on the 
Anatomical Therapeutic Chemical (ATC) system. Pharmacies must register each drug dispensing in 
the prescription registry for cost reimbursement ensuring complete registration.19 During the study 
period, the only NSAID available in Denmark over-the-counter-without a prescription was 
ibuprofen (since November 1, 2001) and only in low (200-mg) doses and in limited quantity (20 
tablets). All other NSAIDS analysed were available by prescription only. The ATC and ICD codes 
are reported in Supplementary Table 1. 
 
Study population and follow up 
We identified a cohort of oral anticoagulant (OAC)-naïve patients aged 30-95 years with AF on the 
day they claimed a first-time prescription for VKA (i.e. warfarin or phenprocoumon), dabigatran, 
rivaroxaban, or apixaban between August 22nd, 2011 and June 30th 2017.20 The date of first-time 
OAC prescription claim defined the inclusion day. We defined doses of apixaban 5mg twice daily, 
dabigatran 150mg twice daily and rivaroxaban 20mg once daily as standard dosage and 
corresponding doses of 2.5mg, 110mg and 15mg as reduced dosage. The exclusion criteria were: 
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history of valvular disease (e.g. mitral stenosis); total hip or knee arthroplasties within five 
weeks before inclusion day; pulmonary embolism or deep vein thrombosis within six months before 
inclusion day; or two prescriptions of different OACs claimed at inclusion. Very few patients 
claimed edoxaban which was also excluded. The diagnosis of AF in the National Patient Registry is 
validated with a positive predictive value of 99%. 21 
 
NSAID Treatment 
We identified all claimed prescriptions for the NSAIDs most commonly prescribed in Denmark: 
celecoxib, diclofenac, ibuprofen, and naproxen. Patient exposure was calculated by estimating a 
daily dose after comparing the accumulated dose and the elapsed time from consecutive 
prescriptions for each drug. Ongoing exposure was then calculated by dividing the number of 
tablets dispensed by the estimated average dosage. If only one prescription was registered for a 
patient, a standard dose, defined as the minimal recommended dose, was used to estimate the daily 
dose. We defined exposure as the time during which patients had medication available and 
discontinuation as the time at which patients had no more medication available. The method has 
been described previously.22-24  
 
For most patients, treatment regimens changed during the study period. The NSAID exposure was 
therefore created as time-varying covariates. Patients were allowed in only one NSAID drug 
exposure group at a time but could change groups according to claimed prescriptions. To 
characterize the study population according to NSAID use, we also defined use as any prescription 
within 180 days from OAC initiation. 
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Comorbidity and concomitant pharmacotherapy 
Comorbidities were defined from ICD codes recorded within 10 years prior to inclusion day. 
Concomitant pharmacotherapy was identified by ATC codes of prescriptions dispensed 180 days 
before inclusion day (Supplementary Table 1). The CHA2DS2-VASc (Congestive heart failure, 
Hypertension, Age >=75 years, Diabetes, Stroke/Transient ischemic attack (TIA), Vascular disease, 
Age 65-74 years, Female sex) score was defined from the registries as described previously.25 The 
score accurately predicts stroke risk in AF populations.22 Similarly, bleeding risk was defined using 
a modified HAS-BLED (Uncontrolled hypertension, Abnormal renal/liver function, Stroke, 
Bleeding, Labile international normalized ratio (INR), Elderly [>=65 years], Drugs [NSAIDs, 
antiplatelet agents, alcohol intake]) score.25 Labile INR’ was omitted, because INR values were not 
recorded in the registries. NSAIDs were also omitted as this was a main explanatory variable. 
Antiplatelet treatment at baseline was defined by prescription of acetylsalicylic acid or non- 
acetylsalicylic acid (clopidogrel, ticagrelor, prasugrel, dipyramadol) agents in the 6-months prior to 
inclusion. 
 
Outcome 
The primary outcome of gastrointestinal bleeding was defined as hospitalization for bleeding 
gastrointestinal ulcer, hematemesis, melena, or unspecified gastrointestinal bleeding from the 
Danish National Patient Registry.26 The register do not provide data on bleeding severity other than 
fatal and non fatal.  A fatal gastrointestinal bleed was defined if the patient died the same day as 
hospitalization or within 30 days. Occurrence and type of bleeding as recorded in hospital databases 
have shown a positive predictive value of 89%-99%.27 
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Statistical analysis 
For each year during the study period (2011-2017), the rates of (concomitant) use of NSAID before 
and after the date of OAC initiation were calculated as number of NSAID users per 100 person-
years within 180 days before and after OAC initiation. 
 
For the main analysis, patients were included between January 1, 2012 and December 31, 2015 and 
followed for 2 years until June 30, 2017 or until the occurrence of gastrointestinal bleeding, death, 
switch to another OAC, or OAC discontinuation (defined as 30 days after unavailability of tablets). 
The restriction of the study period (2012-2015) was used to guarantee that all OACs were on the 
market and prescribed sufficiently to allow an analysis. Baseline was set as the OAC treatment start 
date (inclusion day). 
 
Multiple Cox regression was used to associate current treatment regime with the rates of 
gastrointestinal bleeding where concomitant NSAID therapy was treated as a time-varying 
covariate. A second Cox regression model was used to associate the current treatment regime with 
the hazard rate of the competing risk (all-cause death without bleeding). We adjusted both models 
for year, age (grouped), sex, and all the individual components in the modified HASBLED model: 
chronic kidney disease, alcohol abuse, hypertension, previous bleeds, concomitant aspirin/anti-
platelet treatment, stroke and abnormal liver function. We reported hazard ratios (HRs) with 95% 
confidence intervals (CIs). Based on the Cox regression models for bleeding and death, we also 
calculated the patient-specific absolute risks of gastrointestinal bleeding during a 14-day period of 
concomitant NSAID therapy (versus no concomitant NSAID therapy) see supplementary Figure 1 
for the formula.28 We reported the differences in absolute 14-day risks (ARD) for the periods 90-
104 days and 365-379 days after inclusion day as average treatment effects, among all patients.  
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz069/5631912 by Aalborg U
niversity Library user on 20 N
ovem
ber 2019
10  
 
Confidence intervals for ARDs were obtained based on 1,000 bootstrap data sets. 
 
As sensitivity analyses, we included all patients with OAC initiation in the period August 22, 2011 
through June 30, 2017 and performed analyses for standard and reduced NOAC dosages when 
NSAID therapy was added.  The level of statistical significance was set at 5%. Data management 
and statistical analyses were performed using SAS 9.4,(SAS Institute), Stata 11.0 (StataCorp) and R 
[R Foundation for Statistical Computing; https://www.R-project.org]. 
 
 
Ethics 
In Denmark by law, retrospective registry studies do not require ethics approval. The Danish Data 
Protection Agency approved this study (No 2007-58-0015; GEH-2014-014, I-Suite 02732) and 
provided the data in anonymized form.  
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Results 
During the observation period (Figure 1), NSAID use decreased during the 180 days following 
OAC initiation compared with the same period prior to initiation (Figure 2). NOACs displaced 
VKA as the anticoagulants of choice among patients with AF (Figure 3A). By 2017 some 90% of 
those newly-initiated OACs were prescribed a NOAC compared with 10% prescribed VKA. Co-
prescribing of NSAIDs with OACs declined slightly over time, but compared with patients taking 
VKA, greater proportions taking NOACs were co-prescribed a NSAID, mean 18% versus 21% in 
2016 (Figure 3B). 
In total, 41,183 patients with AF in the period January 1, 2012 until December 31, 2015 were 
included in the study (Figure 1). The mean age was 70.2 years (standard deviation 11.1, median age 
70 years, interquartile range 64-78)) and 54.6% were men. Some 16,722 (40.6%) used VKA, 7,158 
(17.4%) apixaban, 5,665 (13.7%) rivaroxaban, and 11,638 (28.3%) dabigatran. The proportions of 
patients prescribed reduced NOAC dosages were 36%, 27%, and 39% for apixaban, rivaroxaban 
and dabigatran, respectively.  During the study period 3,317 (8.1%) died while 5,450 (13.2%) 
switched to another OAC and 14,204 (34.5%) discontinued OAC treatment. 
 
 
Gastrointestinal Bleeding 
There were 1,642(4.0%) gastrointestinal bleeding events among the study cohort during follow-up 
of which 213 (13,0%) were fatal during hospitalization. Ninety days after the inclusion, the 
differences in absolute risk of GIB within 14 days with versus without concomitant NSAID therapy 
were 0.10 (0.04-0.18) for NOAC and 0.13(0.03-0.24) for VKA. (Figure 4)  
Compared with VKA alone, NOACs overall were associated with lower rates of gastrointestinal 
bleeding (HR 0.78 [95%CI 0.70-0.86]) but concomitant NSAID therapy significantly increased the 
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rates in both cases: NOACs overall, HR 2.01 [95% CI 1.40-2.61]; VKA, HR 1.95 [95% CI 1.21-
2.69]. 
Compared with the individual OAC treatments alone, concomitant NSAIDs conferred a 
significantly elevated HR of gastrointestinal bleeding for apixaban (HR 2.98[95%CI 1.51-4.44]) 
and VKA (HR 1.95 [95%CI 1.21-2.69]), with similar trends also for dabigatran (HR 1.52 [95%CI 
0.76-2.28] and rivaroxaban (HR 1.94 [95%CI 0.77-3.12]) (Figure 4). 
 
Supplemental analyses 
For the period August 22, 2011 through June 30, 2017, we included 60,523 patients with 2,164 
gastrointestinal bleeding events. For individual OAC regimens, concomitant NSAID therapy was 
associated with significantly elevated HRs for apixaban (HR 2.88 [95% CI 1.90-4.35]), rivaroxaban 
(HR 1.64 [95% CI 1,00-2.45]), dabigatran (HR 1.61 [95% CI 1.02-2.55])), and VKA (HR 2.08 
[95% CI 1.49-2.91]) compared with each OAC on its own. Analyses for NSAIDs added to standard 
or reduced NOAC dosages had similar results to the main analyses (please see Supplemental Table 
2) We made a stratified analyses with and without antiplatelets agents. The results remained the 
same (please see Supplemental Table 3). Furthermore we made a stratified analysis if PPI use was 
present at baseline (Please see Supplemental Table 4). 
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Discussion 
Our Danish nationwide study including 41,183 OAC-naïve patients with  AF initiating VKA or 
NOAC treatment found that concomitant NSAID therapy was associated with a doubling of the risk 
of gastrointestinal bleeding compared with an OAC alone. While significant the added risk was also 
modest for a typical couse of therapy of two weeks as shown in figure 4. 
 
People with AF have increased risk of stroke and thromboembolism.29  The risk is reduced with 
anticoagulation but at the cost of increased bleeding risks. While NOACs are associated with lower 
overall rates of bleeding than warfarin, the randomized studies found this was due mainly to 
decreased intracerebral bleeding and there was no clear advantage in respect of gastrointestinal 
bleeding.4-6 Both Kent et al and Davidson et al found in post-hoc analyses of RE-LY and 
EINSTEIN study data that use of NSAIDs among patients taking OACs was associated with 
increased risk of major bleeding, including gastro-intestinal bleeding, compared with non-use.30,31 
Our observational study showed that NOACs were associated with less gastrointestinal bleeding 
than VKA but concomitant NSAIDs abolished this advantage.30,31 Unlike warfarin, antidotes for 
NOAC-associated bleeding are agent-specific; idarucizumab for dabigatran reversal is approved by 
US and European medicines regulators, while  andexanet alpha is approved in the US for apixaban- 
and rivaroxaban-associated bleeding and is awaiting approval in Europe.32, 33 Nevertheless, in 
Denmark as in other countries, NOACs are increasingly the preferred anti-coagulation option in 
newly diagnosed AF.3 
The absolute risk with dabigatran was 0.05 (0.02-0.15). It is lower than apixaban and rivaroxaban. 
Dabigatran has previously been showed to have a higher risk of GI bleeding, The reason we found a 
lower risk might be the fact that people with risk of GI bleeding would be prescribed with a reduced 
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dose and one of the other NOACs. (Supplemental table 2). Previous studies have found same results 
with reduce dosis of Dabigatran. 
 
We have previously shown that NSAIDs co-prescribed with warfarin confer a substantial 
independent risk of bleeding in AF patients.14 The current study, which includes a more 
contemporary AF population, shows that the risk extends to NOACs. Despite this, NSAID 
prescribing was consistently higher among patients on NOACs than among those on VKA. 
 
Non-variceal upper gastrointestinal bleeding and mortality rates have fallen over the past twenty 
years, attributed partly to more judicious use of NSAIDs, but the case fatality rate has remained 
constant at around 5%-6%.13,29 This appears to be related to pre-existing co-morbidities as well as to 
bleeding events acutely. In this study among patients at risk of bleeding owing to factors including 
anticoagulant use, older age, and multiple co-morbidities, 13% of those experiencing 
gastrointestinal bleeding died during hospitalization. Patients who were prescribed concomitant 
NSAIDs had significantly greater risk of associated bleeding compared with those prescribed an 
OAC without a concomitant NSAID. The finding that NSAIDs were co-prescribed to 14.6% of 
people taking OACs and that those taking NOACs had higher rates of co-prescribing than those 
taking VKA is therefore of substantial public health concern given the widespread use of both 
OACs and NSAIDs and the age and co-morbidity profiles of the patients. 
 
NSAID co-prescribing may reflect misconceptions about the relative safety of NOACs and warfarin 
and application of overall bleeding risk data for NOACs to individual bleeding sites. Treatment 
information for both prescribers and patients does not emphasise gastrointestinal (or other) bleeding 
risks potentially associated with NOAC and NSAID co-prescribing. In the US, Food and Drug 
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Administration (FDA) summaries of product characteristics (SpCs) for NOACs note (Sections 5 
and 7) that ‘drugs affecting haemostasis may increase risk of bleeding’ and include ‘NSAIDs’, 
some SpCs specifying ‘chronic’ NSAID use only (apixaban and dabigatran).34-37 Patient 
Information Leaflets list drugs where concomitant use increases bleeding risk. All include NSAIDs 
as a group but provide no examples of named agents and ‘long-term or chronic’ use, as opposed to 
any use, is specified for apixaban and dabigatran.  
 
The European Medicines Agency (EMA) SpCs for NOACs (Sections 4.4, 4.5) issue general 
cautions on ‘care’ when prescribing other medicinal products affecting haemostasis. For both 
apixaban and rivaroxaban, the SpC advises that “Care is to be taken if patients are treated 
concomitantly with NSAIDs (including acetylsalicylic acid)”, and for dabigatran, notes that 
‘chronic use’ but not short-term peri-operative use of NSAIDs with dabigatran increased bleeding 
risk.38-41 Patient Information Leaflets counsel patients to ‘tell your doctor or pharmacist’ about 
multiple concomitant medicines including ‘anti-inflammatory or pain-relieving’ treatments, naming 
two examples, naproxen and acetylsalicylic acid.  
 
In contrast, warfarin SpCs and Patient Information Leaflets include considerably stronger warnings 
about NSAID-associated bleeding risks and name commonly used NSAIDs.42-43  
 
In the context of one in six AF patients initiating NOACs being prescribed concomitant NSAIDs 
within two years and the associated doubling of gastrointestinal bleeding risks found among the 
cohort studied here, it seems prudent to urgently strengthen concomitant medication cautions for 
prescribers and patients alike so that they are at least equivalent to those for warfarin. 
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Limitations 
The main limitation of this study was the observational design. There is a lack of information about 
important clinical parameters serum creatinine, haemoglobin, INR, and body mass index. In the 
nationwide prescription registry, all Danish pharmacies are required to register all dispensed 
prescriptions, ensuring complete registration. Not all prescription NSAIDs were examined, but 
rather only those NSAIDS that were "most commonly” prescribed in Denmark. The only NSAID 
available in Denmark without a prescription is ibuprofen. Patients who used OTC ibuprofen only 
would be classified as nonusers, because they do not claim a prescription in the study period. 
However, we believe this potential misclassification had only a small, if any, influence on the 
findings. Furthermore, if there was a significant effect of OTC use on our results, this would 
influence the results by moving the risk estimates toward the null and hence dilutes any association 
between exposure and outcome. We did not have information on whether patients stopped taking 
OACs when treated with NSAIDs but given treatment guidelines, this was unlikely. We selected 
14-day windows following prescription dispensings to be as sure as possible that the patients were 
likely to be taking NSAID treatment. Furthermore, the time-frame of 14 days allowed comparison 
of all the individual groups in the same way. We could not exclude possible effects of unmeasured 
confounders. Among potential confounders, data were unavailable on serum creatinine, 
haemoglobin, INR, and body mass index. We did not have information about the NSAID treatment 
indication, but as NSAIDs are not indicated for heart disease, this was likely to be for non-cardiac 
disease.  
Another limitation is the effect of information bias. The patients do not necessarily take their 
medications consecutively, leading to the fact that the prescription may run longer and the patients 
therefore are exposed later than the database might indicate. There would be no measurable 
consequences for the rest of the population, because data from individuals taking therapy without 
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being identified as being on a prescription would be diluted in the data from the much larger 
population not on therapy. 
We defined discontinuation as no consecutive dispensed prescription of the initiated OAC within 30 
days after the end of a package. Discontinuation or treatment switching might arise due to side 
effects or unexpected outcomes that could under- or over-estimate the associated risk of 
gastrointestinal bleeding. We stopped following patients who discontinued or switched OAC 
treatment and thereby tried to overcome the associated problems. The definition of fatal events in 
our data set was hospitalization with gastrointestinal bleeding and death from any cause within 30 
days. Indeed, any hospitalization is associated with increased mortality in studies such as ours and 
the possibility exit that patients could have been hospitalized for more than one condition (e.g. 
admitted with pneumonia/sepsis, then developing gastrointestinal bleeding in the intensive care unit 
– predicted mortality for such a patient would be quite high). Compared to the randomized trials, we 
did not have the possibility to adjudicate events through assessment of charts, procedures or other 
follow-up. Together with inclusion of non-selected individuals (compared to the often lower risk 
and homogenous inclusion in trials), we believe this readily explain the difference of the case-
fatality rate between trials and our observational study. 
 
 
Conclusions 
Among Danish AF patients prescribed NOAC treatment, concomitant NSAID therapy was 
associated with a doubling of the risk of gastrointestinal bleeding compared with NOAC treatment 
alone. This aligns with findings from post-hoc analyses of data from large randomised trials that 
evaluated NOACs, RE-LY and EINSTEIN.  
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In our study, patients prescribed NOACs were more likely than those prescribed VKA to be co-
prescribed NSAIDs. As patients with AF taking OACs are already at increased risk of 
gastrointestinal bleeding compared with background rates in the population at large, further 
unintended or un-necessary increase in their risks is a public health concern. Given trends towards 
increasing use of NOACs rather than VKA in AF, prescribers should be reminded of current 
evidence that NOACs are not superior to warfarin in respect of gastrointestinal bleeding risks and 
should exercise high levels of caution when prescribing NSAIDs for AF patients taking NOACs. 
Strengthening of prescribing and patient information regarding the risks of NOAC-NSAID co-
prescribing are likely to be of public health benefit.  
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Table 1 Study population characteristics of the individual treatment groups without and with concomitant NSAID therapy at 
the date of first-time OAC prescription 
VKA VKA+NSAID Apixaban 
Apixaban+ 
NSAID 
Rivaroxaban 
 
Rivaroxaban+ 
NSAID 
 
Dabigatran 
Dabigatran+NSAID 
Characteristic N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Total patients 16024  698 6850 308 
  
     5433 232 11092 546 
Reduced dosage - - 2512(36.7%) 83(27.0%) 1443(26.6%) 66(28.5%) 4362(39.3%) 185 (33.88) 
Age, median (IQR) 71 (64, 78) 69 (63, 77) 72 (65, 80) 68 (62, 77) 71 (64, 80) 70 (63, 76) 69 (63, 77) 67 (61, 75) 
Sex 9196 (57.4%) 418 (59.9%) 
3420 
(49.9%) 173(56.2%) 2738 (50.4%) 122 (52.6%) 
6163 
(55.6%) 326 (59.7%) 
Year         
2012 
4792 (29.9%) 238 (34.1%) 0 (0.0%) 0 (0.0%) 329 (6.1%) 19 (8.2%) 3371 
(30.4%) 
162 (29.7%) 
2013 
4406 (27.5%) 179 (25.6%) 487 (7.1%) 27 (8.8%) 1289 (23.7%) 48 (20.7%) 3680 
(33.2%) 
176 (32.2%) 
2014 
3652 (22.8%) 155 (22.2%) 2298 
(33.5%) 
102 (33.1%) 1304 (24.0%) 55 (23.7%) 3014 
(27.2%) 
149 (27.3%) 
2015 
3174 (19.8%) 126 (18.1%) 4065 
(59.3%) 
179 (58.1%) 2511 (46.2%) 110 (47.4%) 1027 (9.3%) 59 (10.8%) 
CHA2DS2-VASc         
High ( >1) 
12685 
(79.2%) 
547 (78.4%) 5609 
(81.9%) 
238 (77.3%) 4346 (80.0%) 183 (78.9%) 8299 
(74.8%) 
404 (74.0%) 
Int (1) 
2217 (13.8%) 105 (15.0%) 880 (12.8%) 51 (16.6%) 787 (14.5%) 39 (16.8%) 1850 
(16.7%) 
88 (16.1%) 
Low (0) 1122 (7.0%) 46 (6.6%) 361 (5.3%) 19 (6.2%) 300 (5.5%) 10 (4.3%) 943 (8.5%) 54 (9.9%) 
Modified Hasbled         
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High (>2) 
6624 (41.3%) 265 (38.0%) 2858 
(41.7%) 
116 (37.7%) 2142 (39.4%) 87 (37.5%) 3710 
(33.4%) 
183 (33.5%) 
Int    (2) 
7796 (48.7%) 360 (51.6%) 3411 
(49.8%) 
164 (53.2%) 2828 (52.1%) 123 (53.0%) 6009 
(54.2%) 
287 (52.6%) 
Low  (0-1) 
1604 (10.0%) 73 (10.5%) 581 (8.5%) 28 (9.1%) 463 (8.5%) 22 (9.5%) 1373 
(12.4%) 
76 (13.9%) 
Hypertension 
10348 
(64.6%) 483 (69.2%) 
4380 
(63.9%) 205 (66.6%) 3449 (63.5%) 159 (68.5%) 
6599 
(59.5%) 339 (62.1%) 
Stroke 2270 (14.2%) 93(13.3%) 
1421 
(20.7%) 49 (15.9%) 984 (18.1%) 29 (12.5%) 
1662 
(15.0%) 64 (11.7%) 
Cronic kidney 
disease 1308 (8.2%) 44 (6.3%) 322(4.7%) 13 (4.2%) 199 (3.7%) 12 (5.2%) 210 (1.9%) 10 (1.8%) 
Vascular diease 2308 (14.4%) 75 (10.7%) 703 (10.3%) 31 (10.1%) 481 (8.9%) 20 (8.6%) 999 (9.0%) 41 (7.5%) 
Prior Bleeding 1973 (12.3%) 77 (11.0%) 908 (13.3%) 42 (13.6%) 605 (11.1%) 21 (9.1%) 
1186 
(10.7%) 54 (9.9%) 
Liver failure 258 (1.6%) 17(2.4%) 99 (1.4%) 3(1.0%) 66 (1.2%) 3 (1.3%) 122 (1.1%) 6 (1.1%) 
Alcohol 495 (3.1%) 26(3.7%) 239 (3.5%) 9 (2.9%) 171 (3.1%) 8 (3.4%) 347 (3.1%) 25 (4.6%) 
Peripheral arterial 
disease 
690 (4.3%) 
19 (2.7%) 232 (3.4%) 10 (3.2%) 179 (3.3%) 7 (3.0%) 265 (2.4%) 14 (2.6%) 
Antiplatelet 7742 (48.3%) 307(44.0%) 
3048 
(44.5%) 136(44.2%) 2474 (45.5%) 103 (44.4%) 
4680 
(42.2%) 226 (41.4%) 
 ADP receptor 
antagonists  
 
2178 (13.6%) 72 (10.3%) 959 (14.0%) 40 (13.0%) 710 (13.1%) 
 
19 (8.2%) 
1200 
(10.8%) 
 
50 (9.2%) 
Aspirin 
6848 (42.7%) 
282 (40.4%) 
2461 
(35.9%) 119 (38.6%) 2054 (37.8%) 
94 (40.5%) 4059 
(36.6%) 
201 (36.8%) 
Proton pump 
inhibitor 3687 (23.0%) 248 (35.5%) 
1614 
(23.6%) 99 (32.1%) 1181 (21.7%) 89(38.4%) 
2064 
(18.6%) 168 (30.8%) 
 
 
Legend: Study population characteristics of the individual OACs groups with and without NSAID. Numbers and percentages of first-time 
initiators of vitamin K antagonists (VKA), dabigatran, rivaroxaban, and apixaban.  
50 
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Figure 1 Selection of the study population  
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Patients initiated first time on OAC
from August 22, 2011 to June 1, 2017
 n=83,131
Excluded:
Age <18 or  >95, n=324
No history of AF, n=19,328
History of potential valvular AF, n=304
Venous thrombosis within six months before inclusion, n=1,996
Total hip or knee arthroplastic
surgery within five weeks before inclusion, n=464
Edoxanban as first OAC, n=159
Two different OAC prescriptions at inclusion, n=33
AF patients initiated on OAC, n=60,523,
Warfarin, n=21,753, Apixaban, n=13,484, Rivaroxaban, n=11,451, Dabigatran, n=13,471
Patients included between 2012−2015, n=41,183
VKA,
n=16,722
Apixaban,
n=7,158
Rivaroxaban
n=5,665
Dabigatran
n=11,638
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Figure 2 Rates of NSAID usage as concomitant therapy per 100 person years during the 180 days before and the 180 days following OAC 
initiation. 
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Figure 3A Percentage of VKA and NOAC initiation according to calendar year. 
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Figure 3B Rates of NSAID usage as concomitant therapy per 100 person years during the first 180 days following VKA or NOAC initiation.  
  
  
  
  
●
●
●
●
●
●
●
●
●
●
●
●
18.3
20.2
21.2
25.4
19.9
24.1
20.4
23.4
18.3
22.9
18.4
20.7
0
10
20
30
2011 2012 2013 2014 2015 2016
Year
E
x
p
u
s
u
re
 r
a
te
 1
0
0
 P
Y
● ●VKA+NSAID NOAC+NSAID
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz069/5631912 by Aalborg U
niversity Library user on 20 N
ovem
ber 2019
33  
 
  
Figure 4 Hazard ratios (HR) and absolute 14-day absolute risk differences (ARD) of gastrointestinal bleeding under concomitant NSAID  
therapy relative to OAC therapy without NSAID in patients with atrial fibrillation (AF) adjusted for age, sex, bleeding risk factors incorporated  
in the HAS-BLED score. Abbreviations: NSAID, non-steroidal anti-inflammatory drug; VKA, vitamin K antagonists, NOAC, non-vitamin K  
antagonist oral anticoagulants; CI, confidence interval. Reference is the individual OACs treatment without NSAIDs (Vertical line indicates  
reference level).  
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Supplementary Table 1 
Population   
 atrial fibrillation Defined from diagnosis of atrial 
fibrillation with the absence of 
diagnosis codes of valvular atrial 
fibrillation and mitral- or aortic 
valve surgery. 
Presence of: 
ICD8: 42793, 42794. 
ICD10: I48. 
Absence of: 
ICD8: 4240, 4241, 39500- 39502, 
39508, 39509, 39600-39604, 39608, 
39609. 
ICD10: I05, I06, I080A, I081A, 
I082A, I083A, Z952, Z954. 
NCSP: KFKD, KFKH, KFMD, 
KFMH, KFGE, KFJF. 
Vitamin K antagonist Defined from ATC-code. ATC: B01AA03 
Dabigatran Defined from ATC-code. ATC: B01AE07. 
Rivaroxaban Defined from ATC-code. ATC: B01AF01. 
Apixaban Defined from ATC-code. ATC: B01AF02. 
Non-steroidal anti-
inflammatory drugs 
Defined from ATC-code:  ATC M01A but excluding 
glucosamine (M01AX05), 
Including celecoxib (M01AH01), 
naproxen (M01AE02), diclofenac 
(M01AB05), ibuprofen (M01AE01) 
Hip or knee replacement 
surgery 
Defined from surgical procedure 
performed. 
NCSP: KNFB, KNFC, KNGB, 
KNGC. 
Deep venous thrombosis Defined from diagnosis. ICD10: I801-I803, I808, I809, I821-
I823, I828, I829 
Pulmonary embolism Defined from diagnosis. ICD10: I26. 
 
Comorbidities and outcomes 
 
Stroke Defined from diagnosis of ischemic 
stroke, transient ischemic attack, or 
systemic thromboembolism. 
ICD10: I63, I64, I74, G458, G459. 
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Peripheral artery disease  ICD10: I70 
Hypertension Defined from combination treatment 
with at least two classes of 
antihypertensive drugs: adrenergic 
-antagonists, non-loop diuretics, 
vasodilators, beta-blockers, calcium 
channel blockers and renin-
angiotension system inhibitors.  
ATC: C02A, C02B, C02C, C02L, 
C03A, C03B, C03D, C03E, C03X, 
C07B, C07C, C07D, C08G, 
C02DA, C09BA, C09DA, C02DB, 
C02DD, C02DG, C07A, C07B, 
C07C, C07D, C07F, C08, C09BB, 
C09DB, C09AA, C09BA, C09BB, 
C09CA, C09DA, C09DB, 
C09XA02, C09XA52 
 
Chronic kidney disease Defined from diagnosis of chronic 
glomerulonephritis, chronic 
tubulointestinal nephropathy, 
diabetic, and hypertensive 
nephropathy among others. 
ICD10: E102, E112, E132, E142, 
I120, M300, M313, M319, M321B, 
N02-N08, N11, N12, N14, N18, 
N19, N26, N158, N159, N160, 
N162, N163, N164, N168, Q61, 
Q613, Q615, Q619. 
Abnormal liver function Defined from diagnosis of liver 
chronic liver disease, cirrhosis and 
hepatitis. 
ICD10: B15-B19, C22, D684C, 
I982, K70-K77, Q618A, Z944. 
Bleeding Defined from diagnosis of 
intracranial bleeding, major 
gastrointestinal bleeding, respiratory 
or urinary tract bleeding, and 
bleeding due to anaemia. 
ICD10: D500, D62, G951A, 
H052A, H313, H356, H431, H450, 
I312, I60-I62, I850, I864A, J942, 
K228F, K298A, K250, K252, 
K254, K256, K260, K262, K264, 
K266, K270, K272, K274, K276, 
K280, K282, K284, K286, K625, 
K661, K638B, K638C, K838F, 
K868G , K920, K921, K922, N02, 
R04, R31, S064, S065, S066, 
S368D. 
Alcohol abuse Defined from alcohol-related 
diagnosis codes or at least one 
dispensed prescription of an alcohol 
antagonist drug used to treat chronic 
ICD10: E244, E52,  
F10, G312, G621, G721, I426, 
K292, K70, K860, L278A, O354, 
T51, Z714, Z721. 
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alcoholism. ATC: N07BB. 
 
Concomitant medication 
  
ADP receptor antagonists Defined from ATC-code. ATC: B01AC04, B01AC22, 
B01AC24 
Proton pump inhibitors Defined from ATC-code. ATC: A02BC 
 
Outcomes 
  
Gastrointestinal bleeding Defined from  ICD10: K250, K254, K260, K264, 
K270, K280, K920-K922, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2 
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Hazard ratio of gastrointestinal bleeding according to OAC treatment and concomitant NSAID according to dose 
 
 Apixaban Apixaban+NSAID Rivoxaban Rivoxaban+NSAID Dabigatran Dabigatran+NSAID 
 Reduced 
dose  
(2.5 mg 
BID) 
Standard 
dose 
(5 mg 
BID) 
Reduced 
dose  
(2.5 mg 
BID) 
Standard 
dose  
(5 mg 
BID) 
Reduced 
dose 
(15 mg 
OD)) 
Standard 
dose 
(20 mg 
OD)) 
Reduced 
dose 
(15 mg 
OD)) 
Standard 
dose 
(20 mg 
OD)) 
Reduced 
dose 
(110 mg 
BID) 
High 
dose 
 
(150 mg 
BID) 
Reduced 
dose 
(110 mg 
BID) 
High dose 
 
(150 mg 
BID) 
Hazard 
ratio (95% 
CI) 
Ref Ref 4.28 
(2.17-
8.43) 
2.19 
(1.07-
4.47) 
Ref Ref 2.45(0.99-
6.03) 
1.64(0.72-
3.70) 
Ref Ref 1.65 
(0.50-
3.22) 
1.49 
(0.69-
3.17) 
  
  
  
Supplementary Table 3  
Hazard ratio of gastrointestinal bleeding according to OAC treatment and concomitant NSAID stratified by any antiplatelet agents  
Any antiplalets 
18716 patients, 875 events 
  HR low high 
 VKA 1.98 1.20 3.27 
 NOAC 2.17 1.45 3.25 
     
 Apixaban 3.52 1.78 6.94 
 Rivaroxaban 1.68 0.69 4.12 
 Dabigatran 1.79 0.97 3.28 
     
No antiplatelet 
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22467 patients, 767 events   
 VKA 1.92 1.08 3.43 
 NOAC 1.84 1.16 2.92 
     
 Apixaban 2.54 1.25 5.19 
 Rivaroxaban 2.25 0.99 5.11 
 Dabigatran 1.13 0.47 2.76 
 
 
 
 
Supplementary Table 4 
Hazard ratio of gastrointestinal bleeding according to OAC treatment and concomitant NSAID stratified with baseline PPI 
 
PPI 
9150 patienter, 416 events 
  HR low high 
 VKA 1.65 0.84 3.23 
 NOAC 1.45 0.79 2.66 
     
 Apixaban 1.62 0.51 5.17 
 Rivaroxaban 1.83 0.66 5.03 
 Dabigatran 1.10 0.40 2.99 
     
NO PPI 
32033 patients, 1226 event  
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 VKA 2.11 1.33 3.34 
 NOAC 2.27 1.60 3.22 
     
 Apixaban 3.63 2.11 6.26 
 Rivaroxaban 1.91 0.90 4.07 
 Dabigatran 1.72 0.97 3.07 
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Supplementary Figure 1  
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